Last reviewed · How we verify
Matching placebo of AK0529
Matching placebo of AK0529 is a Small molecule drug developed by Shanghai Ark Biopharmaceutical Co., Ltd.. It is currently in Phase 3 development.
This is a placebo control formulation with no active pharmaceutical ingredient.
At a glance
| Generic name | Matching placebo of AK0529 |
|---|---|
| Sponsor | Shanghai Ark Biopharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a matching placebo for AK0529, this product contains inert ingredients formulated to match the appearance, taste, and administration route of the active drug, allowing for blinded comparison in clinical trials. It produces no pharmacological effect and serves solely as a control arm to assess the efficacy and safety of AK0529 relative to no treatment.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Matching placebo of AK0529 CI brief — competitive landscape report
- Matching placebo of AK0529 updates RSS · CI watch RSS
- Shanghai Ark Biopharmaceutical Co., Ltd. portfolio CI